Normalization of long-term quality of life in Crohn�s disease patients receiving ustekinumab | Zendy

Miquel Marquès Camí | Zendy; Virginia Robles | Zendy; Natalia Borruel | Zendy; Claudia HerreradeGuise | Zendy; L Mayorga | Zendy; Francesc Casellas | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Normalization of long-term quality of life in Crohn�s disease patients receiving ustekinumab

Author(s) -

Miquel Marquès Camí,

Virginia Robles,

Natalia Borruel,

Claudia HerreradeGuise,

L Mayorga,

Francesc Casellas

Publication year - 2020

Publication title -

revista española de enfermedades digestivas

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.331

H-Index - 38

eISSN - 2340-4167

pISSN - 1130-0108

DOI - 10.17235/reed.2020.6941/2020

Subject(s) - ustekinumab , crohn's disease , normalization (sociology) , medicine , crohn disease , disease , term (time) , gastroenterology , adalimumab , physics , quantum mechanics , sociology , anthropology

ustekinumab is a fully human monoclonal antibody against IL-12/23, approved for induction and maintenance treatment of Crohn's disease (CD). Real-life data shows its true effectiveness in terms of clinical and endoscopic response. However, there is little information regarding health-related quality of life (HRQoL) in CD patients receiving ustekinumab. The main aim of this study was to define long-term clinical remission and HRQoL normalization. The clinical predictive factors of clinical remission were investigated as a secondary aim.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research